GW Pharmaceuticals continues to deliver rewards to its investors Although there are currently a number of outstanding performing stocks in the cannabis industry, it would be unfair to leave GW
All cannabis stock activity is getting a boost from the upcoming acquisition Before the recent boom in the cannabis industry, marijuana stocks were considered something to play with by certain
The major cannabis company has seen its stock rise following the announcement of the sale From its very inception, GW Pharmaceuticals has concentrated its research and development on medical problems
Analysts suggest the cannabis company is in line to see huge gains this year Not so long ago, investing in the cannabis stock market carried a little cloud along with
The research into using cannabis to treat MS has been progressing for more than a year There is new hope coming out of Europe showing positive results in the treatment
GW Pharmaceuticals teams up with several entities to explore the possibilities The Department of Defense (DOD) is on a mission and, surprisingly, it’s not an active military one. It is
GW Pharmaceuticals could be “the one” moving forward In stock trading, a blue-chip stock is one that represents a company that is large, stable and financially sound. Those companies are
FDA-approved Epidiolex can now be prescribed in the U.S. Following approval by the Food & Drug Administration (FDA) this past June, the first cannabis-based drug for treating epilepsy is now
GW Pharmaceuticals gained an advantage over Tilray with DEA scheduling of Epidiolex on Thursday. Publicly traded GW Pharmaceuticals had a monumental win on Thursday. The company’s cannabis-derived epilepsy drug, Epidiolex,
Stocks in the biotech sector are rising alongside industry leaders Tilray and Canopy Growth Biotechnology is currently the largest and fastest-growing sector of the marijuana industry in the United States.